LP-108 with azacitidine for blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called LP-108 combined with azacitidine for people with certain blood cancers like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It aims to see if the combination is safe and helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML, MDS, or CMML that has come back, hasn't improved, or you can't have standard chemotherapy (for AML) or have high-risk MDS or CMML.
- You are well enough to be up and about (ECOG score 0-2).
- Your blood counts and organ function (liver, kidneys, clotting) are within certain limits.
- You haven't had certain treatments (like a stem cell transplant in the last 3 months, or certain drugs) recently.
- You are willing to use birth control during and for 3 months after the study if you are sexually active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
This trial tests a new drug called Lonitoclax combined with azacitidine for people with AML that has come back or not responded to prior treatment. The study will see if the combination is safe and can help control the leukemia.
This trial tests a new drug called axatilimab, given alone or with another drug, for people with certain blood cancers that are advanced or hard to treat. The goal is to see if this combination can help control the disease.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
This trial tests a combination of drugs for people with AML who, after initial treatment, have very low levels of leukemia still present (called measurable residual disease or MRD). The goal is to wipe out these remaining cells and reduce the chance of the cancer coming back.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.